Clinical Trial Update: Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of selinexor (KPT-330) in female patients with advanced gynecologic malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Carcinoma
• Endometrial Carcinoma
• Ovarian Carcinoma

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Ovarian Carcinoma, Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-02